Embryonics
AI Algorithms for In-vitro Fertilization
Company Overview
Snapshot
Founded in May 2018 by David Silver and Yael Gold-Zamir, Embryonics operates with 1-10 employees. The company raised $4 million across one funding round from 3 investors, including Shustermann Family Investment Office. In January 2024, Embryonics was acquired by Rhea Fertility.
Business overview
Embryonics is a Health Tech & Life Sciences company that develops AI algorithms to enhance in-vitro fertilization (IVF) success rates. The company offers a suite of AI solutions, including custom hormonal protocols, oocyte and embryo selection (CE marked), and non-invasive genetic screening. Its technology, including the UBAR assistive embryo selection tool, aims to transform fertility clinic procedures from art to data-based science, thereby reducing expenses and improving success rates for healthcare providers in the fertility market.
Strategic signal
In January 2024, Embryonics was acquired by Rhea Fertility. This acquisition signals a strategic consolidation within the fertility technology sector, indicating a growing trend towards integrating advanced AI solutions to improve IVF outcomes and streamline clinic operations. For investors, this highlights the commercial viability and strategic value of AI-driven fertility platforms in a competitive healthcare market.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant corporate milestone for Embryonics in early 2024?
- In January 2024, Embryonics was acquired by Rhea Fertility, marking a key exit for the company.
- What was the total capital raised by Embryonics?
- Embryonics raised a total of $4 million across one funding round.
- Which investors participated in Embryonics' funding round?
- In January 2021, Embryonics received funding from Shustermann Family Investment Office and Israel Innovation Authority.
- What was a key partnership for Embryonics in 2022?
- In April 2022, Embryonics announced a partnership with Jaslok-FertilTree International Fertility Centre in India to increase the success rate of fertility treatments in the Indian subcontinent.
- What is Embryonics' core technology for improving IVF success?
- Embryonics utilizes AI algorithms, including its UBAR tool, to predict embryo implantation probability, assist in embryo selection, and offer personalized hormonal treatments, aiming to increase IVF success rates by up to 50%.